Lupus prone NZB/W mice repeatedly exposed to bacterial lipopolysaccharide (LPS) develop enhanced polyclonal B cell activation and exacerbated nephritis by a mechanism that results in increased deposits of immunoreactants in kidneys without measurable impairment of mononuclear phagocyte function. In this paper, we investigate whether the referenced effects of LPS are reversible after withdrawal of LPS, or whether their persistence could contribute to progression of nephritis to chronicity. In NZB/W mice previously exposed to LPS, features of enhanced polyclonal B cell activation, more severe glomerulonephritis with tubulointerstitial involvement, increased deposits of immunoreactants in glomeruli, and altered protein excretion persisted 6 weeks after LPS was discontinued. Additionally, mononuclear phagocyte function, assessed through liver uptake of radiolabeled immune complexes, was found to be impaired. The results indicate that some of the effects of prior exposure to LPS may be partially reversible; however, they last long after LPS has been discontinued, and additional impairment of immune function develops together with permanent glomerular dysfunction, thereby contributing to progression of nephritis to chronicity.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/096120339400300614 | DOI Listing |
Immunotargets Ther
January 2025
CNRS UPR3572, Immunology, Immunopathology and Therapeutic Chemistry, Institute of Molecular and Cellular Biology, Strasbourg, 67084, France.
Purpose: The co-inhibitory receptor B and T Lymphocyte Attenuator (BTLA) negatively regulates B and T cell activation. We have previously shown an altered BTLA expression by regulatory T cells and an impaired capacity of BTLA to inhibit CD4 T cell activation in lupus patients. In this study, we analyzed BTLA expression and function in the NZB/W lupus-mouse model and examined the therapeutic potential of BTLA targeting.
View Article and Find Full Text PDFInt J Mol Sci
December 2024
Department of Food Science and Nutrition, Kyungpook National University, Daegu 41566, Republic of Korea.
Arthritis Res Ther
November 2024
GenNBio Inc, 80, Deurimsandan 2-ro, Cheongbuk-eup, Pyeongtaek-si, Gyeonggi-do, 17796, Republic of Korea.
Int J Mol Sci
October 2024
Rheumatology Research Group-Lupus Unit, Vall d'Hebrón University Hospital, Vall d'Hebrón Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08193 Barcelona, Spain.
Biology (Basel)
September 2024
Immunology Discovery Research, Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!